Inozyme Pharma to Present at the Jefferies Healthcare Conference

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman of the board, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023, from 9:30-9:55 a.m. ET.

A live webcast of the presentation can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. We are developing INZ-701, an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

For more information, please visit www.inozyme.com and follow us on LinkedIn, Twitter, and Facebook.

ContactsInvestors:Inozyme PharmaStefan Riley, Director of IR and Corporate Communications(857) 330-8871[email protected]

Media:SmithSolveMatt Pera(973) 886-9150[email protected]

Source: Inozyme Pharma Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Banco Santander Chile: Second Quarter 2026 Analyst and Investor Webcast / Conference Call
• Outdoor Education Helps Students Build Confidence, Connection, and Curiosity Beyond the Classroom
• Gold Bullion Securities Limited Publication of Prospectus